Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell Lonser

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Neurosurgery|February 2, 2023
Commentary: Two Practices to Improve Informed Consent for Intraoperative Brain ResearchRyan Eaton, Efthimios Parasidis, Russell Lonser
Cell Cycle (Georgetown, Tex.)|October 7, 2009
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteomeZhengping Zhuang, Jie Lu, Russell Lonser, et al.
Expert Review of Neurotherapeutics|May 20, 2020
Gene therapy for Parkinson's disease: contemporary practice and emerging conceptsAristide Merola, Amber Van Laar, Russell Lonser, et al.
Journal of Oncology|May 11, 2010
Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agentsJeffrey Helgager, Jie Li, Irina A Lubensky, et al.
Neurosurgical Focus|January 2, 2015
Introduction: a focus on low-grade gliomaBob S Carter, E Antonio Chiocca, Russell Lonser, et al.
Plos One|February 23, 2011
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapyLucia Martiniova, Jie Lu, Jeffrey Chiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2009
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanismsJie Lu, John S Kovach, Francis Johnson, et al.
Neuro-Oncology|July 14, 2021
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stressPratibha Sharma, Jihong Xu, Katie Williams, et al.
Blood|January 31, 2013
Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomasChunzhang Yang, Michael G Sun, Joey Matro, et al.
Contrast Media & Molecular Imaging|March 13, 2008
A dual CT-MR dendrimer contrast agent as a surrogate marker for convection-enhanced delivery of intracerebral macromolecular therapeutic agentsCeleste Aida S Regino, Stuart Walbridge, Marcelino Bernardo, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Neurosurgery|February 2, 2023
Commentary: Two Practices to Improve Informed Consent for Intraoperative Brain ResearchRyan Eaton, Efthimios Parasidis, Russell Lonser
Cell Cycle (Georgetown, Tex.)|October 7, 2009
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteomeZhengping Zhuang, Jie Lu, Russell Lonser, et al.
Expert Review of Neurotherapeutics|May 20, 2020
Gene therapy for Parkinson's disease: contemporary practice and emerging conceptsAristide Merola, Amber Van Laar, Russell Lonser, et al.
Journal of Oncology|May 11, 2010
Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agentsJeffrey Helgager, Jie Li, Irina A Lubensky, et al.
Neurosurgical Focus|January 2, 2015
Introduction: a focus on low-grade gliomaBob S Carter, E Antonio Chiocca, Russell Lonser, et al.
Plos One|February 23, 2011
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapyLucia Martiniova, Jie Lu, Jeffrey Chiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2009
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanismsJie Lu, John S Kovach, Francis Johnson, et al.
Neuro-Oncology|July 14, 2021
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stressPratibha Sharma, Jihong Xu, Katie Williams, et al.
Blood|January 31, 2013
Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomasChunzhang Yang, Michael G Sun, Joey Matro, et al.
Contrast Media & Molecular Imaging|March 13, 2008
A dual CT-MR dendrimer contrast agent as a surrogate marker for convection-enhanced delivery of intracerebral macromolecular therapeutic agentsCeleste Aida S Regino, Stuart Walbridge, Marcelino Bernardo, et al.
Pageof 3